GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Poll|February 17, 2015
Mini Quiz: Childhood Depression
Author(s)Psychiatric Times Editors
What therapy is considered the "gold standard” in treating childhood and adolescent depression? Find out in this quiz,
Advertisement
Which of the following therapies is considered to be the “gold standard” in treating childhood and adolescent depression?
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5